United Therapeutics (NASDAQ:UTHR) Sets New 12-Month High – Should You Buy?

United Therapeutics Corporation (NASDAQ:UTHR)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $549.50 and last traded at $542.0180, with a volume of 270387 shares traded. The stock had previously closed at $531.82.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Multiple brokerages have increased price targets and reiterated buy/outperform views on UTHR, supporting upside expectations and helping push demand for the shares. MarketBeat summarizes these upgrades and the consensus “Moderate Buy” stance.
• Positive Sentiment: Wells Fargo published a bullish forecast calling for strong price appreciation for United Therapeutics, which likely feeds into the rally as investors chase analyst-led momentum. Wells Fargo forecast
• Neutral Sentiment: Market summaries show very high institutional ownership (~94%) and some hedge funds/institutions increasing stakes; this underscores heavy institutional interest but does not by itself signal direction.
• Neutral Sentiment: Reported short-interest entries show zero shares/NaN in the feed (likely a data/reporting anomaly). Current short-interest metrics appear unreliable in these notices and should be treated cautiously until official exchange data is posted.
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (avg ~$525–$527) and CFO James Edgemond sold 10,000 shares (avg ~$527.48) in late March—transactions worth roughly $5M+ each. Large insider sales can create short-term selling pressure or raise governance/ownership questions for some investors. SEC filings for the CEO and CFO sales are linked. CEO Rothblatt SEC filing CFO Edgemond SEC filing

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on UTHR shares. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Royal Bank Of Canada boosted their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $549.91.

United Therapeutics Trading Up 1.8%

The business has a fifty day moving average of $492.27 and a 200-day moving average of $470.84. The firm has a market cap of $23.74 billion, a PE ratio of 19.41, a PEG ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $6.19 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,938,901.40. This represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 336,820 shares of company stock valued at $166,359,058 in the last 90 days. Corporate insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC raised its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP increased its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC increased its stake in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the last quarter. Invesco Ltd. raised its position in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.